NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on developing nanomaterials for antiviral therapy, announced today that it will participate in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and other interested parties from 9:45 a.m. to 2:45 p.m. ET.
The company's participation underscores its commitment to advancing its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. According to the press release, NV-387 is unique in its broad-spectrum activity, also proving effective in animal models for monkeypox (MPox), smallpox, and measles.
NanoViricides has successfully completed a Phase I human clinical trial of NV-387 in healthy volunteers, with no reported adverse events. The company is now focused on advancing the drug into Phase II human clinical trials. This progress is significant given the ongoing need for effective treatments against a range of viral threats, particularly in the context of evolving respiratory viruses.
The company also highlighted its other advanced drug candidate, NV-HHV-1, which is being developed for all herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (shingles and chickenpox). However, the company noted that it cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to reliance on external collaborators and consultants.
This conference appearance provides an opportunity for NanoViricides to engage with the investment community and discuss its pipeline and strategic direction. The company's focus on broad-spectrum antivirals addresses a critical gap in pandemic preparedness and treatment of viral diseases that affect millions worldwide. If NV-387 proves successful in Phase II trials, it could offer a much-needed therapeutic option for multiple viral infections, potentially reducing the burden on healthcare systems and improving patient outcomes.
For more information about NanoViricides, visit the company's website at www.nanoviricides.com. Additional updates are available in the company's newsroom at https://ibn.fm/NNVC.
